This company has been marked as potentially delisted and may not be actively trading. Revelation Biosciences (REVBU) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock REVBU Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Revelation Biosciences files to sell 13.07M shares of common stock for holdersSeptember 16, 2025 | msn.comRevelation Biosciences Raises $9.6M Through Warrant ExerciseSeptember 15, 2025 | msn.comRevelation Biosciences, Inc.: Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical DataSeptember 10, 2025 | finanznachrichten.deRevelation Biosciences announces webcast to review Phase 1b PRIME dataSeptember 10, 2025 | msn.comGroundbreaking Results from REVB Point to Relief for MillionsSeptember 9, 2025 | finance.yahoo.comRevelation Biosciences Stock Slides 17% After Company Reports 3 Severe Adverse Events In Early Stage Trial Of Inflammation DrugSeptember 9, 2025 | msn.comRevelation Biosciences, Inc.: Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical StudySeptember 9, 2025 | finanznachrichten.deREVB To Release Test Results This QuarterAugust 8, 2025 | msn.comRevelation Biosciences reports Q2 EPS ($7.01) vs. ($246.27) last yearAugust 8, 2025 | msn.comInvestors Should Look at REVB as Top-Line Results ApproachJuly 9, 2025 | finance.yahoo.comREVB Revelation Biosciences, Inc. - Seeking AlphaJuly 5, 2025 | seekingalpha.comRevelation Biosciences Stock Sinks 12% After Reverse Split Reveal; Retail Traders Eye ‘Bigger News’July 2, 2025 | msn.comRevelation Biosciences announces 1-for-3 reverse stock splitJuly 2, 2025 | msn.comREVB Announces Major Treatment ExpansionApril 29, 2025 | msn.comREVB Announces Positive Test ResultsMarch 17, 2025 | msn.comRevelation Biosciences: Gemini priming attenuates inflammatory response in PBMCsMarch 17, 2025 | markets.businessinsider.comRevelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024March 8, 2025 | businesswire.comREVB Starts 2025 With Bright Future AheadMarch 7, 2025 | msn.comRevelation doses first patient in PRIME Phase 1b clinical studyFebruary 27, 2025 | markets.businessinsider.comRevelation Biosciences receives continued Nasdaq listing approvalFebruary 24, 2025 | markets.businessinsider.comRevelation Biosciences files for secondary offering of common stockDecember 12, 2024 | msn.comREVB Results Set Stage for Future GrowthNovember 12, 2024 | msn.comWhy Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving PremarketNovember 11, 2024 | benzinga.comRevelation Biosciences (NASDAQ:REVB) Stock, Insider Trading ActivityOctober 4, 2024 | benzinga.comRevelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10September 24, 2024 | finance.yahoo.comBio-Techne Corporation (TE1.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comREVB Stock Earnings: Revelation Biosciences Misses EPS for Q2 2024August 9, 2024 | markets.businessinsider.comREVB: In Great Position For TestingMay 13, 2024 | msn.comREVB Begins Trials with Good Cash on HandMarch 25, 2024 | msn.comRevelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth ConferenceMarch 12, 2024 | finance.yahoo.comRevelation Biosciences starts phase 1 trial for GeminiMarch 6, 2024 | investing.comRevelation Biosciences (REVB) Price Target Increased by 242.79% to 40.04February 24, 2024 | msn.comRevelation Biosciences Inc Ordinary SharesFebruary 15, 2024 | morningstar.comMRevelation Biosciences Regains Nasdaq Compliance with OfferingFebruary 9, 2024 | msn.comWhy Is Revelation Biosciences (REVB) Stock Up 61% Today?January 29, 2024 | markets.businessinsider.comRevelation Biosciences (REVB) Price Target Decreased by 23.67% to 11.68July 6, 2023 | msn.comRecap: Revelation Biosciences Q1 EarningsMay 22, 2023 | msn.comRevelation Biosciences Shares Drop 30% After Public Offering PricesFebruary 9, 2023 | marketwatch.com'UFOs are real!' Former Department of Defence official makes astonishing revelationJanuary 13, 2023 | mirror.co.ukMRevelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023January 10, 2023 | finance.yahoo.comRevelation Biosciences (Nasdaq:REVBU) HeadlineTrading was temporarily halted for "REVBU" at 09:07 AM with a stated reason of "LULD pause."...July 28, 2022 | marketbeat.comRevelation Biosciences (Nasdaq:REVBU) HeadlineTrading was temporarily halted for "REVBU" at 09:07 AM with a stated reason of "LULD pause."...July 25, 2022 | marketbeat.comRevelation Biosciences (Nasdaq:REVBU) HeadlineTrading was temporarily halted for "REVBU" at 09:07 AM with a stated reason of "LULD pause."...July 25, 2022 | marketbeat.comRevelation Biosciences (Nasdaq:REVBU) HeadlineTrading was temporarily halted for "REVBU" at 10:07 AM with a stated reason of "LULD pause."...July 22, 2022 | marketbeat.comRevelation Biosciences (Nasdaq:REVBU) HeadlineTrading was temporarily halted for "REVBU" at 10:07 AM with a stated reason of "LULD pause."...July 22, 2022 | marketbeat.comRevelation Biosciences (Nasdaq:REVBU) HeadlineTrading was temporarily halted for "REVBU" at 09:07 AM with a stated reason of "LULD pause."...July 22, 2022 | marketbeat.comRevelation Biosciences (Nasdaq:REVBU) HeadlineTrading was temporarily halted for "REVBU" at 03:04 PM with a stated reason of "LULD pause."...April 8, 2022 | marketbeat.comRevelation Biosciences (Nasdaq:REVBU) HeadlineTrading was temporarily halted for "REVBU" at 08:03 AM with a stated reason of "News pending."...March 30, 2022 | marketbeat.comRevelation Biosciences (Nasdaq:REVBU) HeadlineTrading was temporarily halted for "REVBU" at 12:03 PM with a stated reason of "LULD pause."...March 9, 2022 | marketbeat.comRevelation Biosciences (Nasdaq:REVBU) HeadlineTrading was temporarily halted for "REVBU" at 12:01 PM with a stated reason of "LULD pause."...January 20, 2022 | marketbeat.com Get Revelation Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for REVBU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. REVBU Media Mentions By Week REVBU Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REVBU News Sentiment▼0.030.77▲Average Medical News Sentiment REVBU News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REVBU Articles This Week▼00▲REVBU Articles Average Week Get the Latest News and Ratings for REVBU and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Revelation Biosciences and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SXTPW News DRTSW News BCTXW News ENGNW News FBIOP News GOVXW News JSPRW News NAMSW News NTRBW News RVPHW News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:REVBU) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredTexit: The $1.4 trillion reason why tech is fleeing Cali for TexasThe state of Texas recently made a critical change to its laws… In a quest to become the AI data center cap...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revelation Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revelation Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
